News releases from Allergan plc
Allergan's Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications
May 16, 2017
-- Approximately Half of Americans Surveyed Notice the Eyes First, Supporting the Mission of the Campaign to Empower Chronic Dry Eye Sufferers to Take Action --
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 33rd Annual Strategic...
Allergan plc (NYSE: AGN) ("Allergan" or the "Company") today announced that, subject to market and other conditions, the Company expects to commence an offering of euro-denominated senior unsecured...
Allergan plc (NYSE: AGN) today announced that its indirectly wholly owned subsidiaries Allergan Funding SCS, Allergan Finance LLC, Forest Laboratories, LLC and Allergan, Inc., each as co-offeror with...
Allergan Reports Solid Start to 2017 with 5% Increase in First Quarter GAAP Net Revenues to $3.6 Billion
May 09, 2017
- Q1 2017 GAAP Continuing Operations Loss Per Share of $7.85; Q1 Non-GAAP Performance Net Income Per Share of $3.35 -
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders and Chief Research & Development Officer David Nicholson will participate in a...
Allergan to Present New Data at the 2017 American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting in San Diego
May 04, 2017
Allergan plc (NYSE: AGN), a leading global pharmaceutical company in women's healthcare, will present new data from its women's healthcare portfolio, at the annual American College of Obstetricians and...
Allergan to Present New and Updated Linzess®, Viberzi®, Relamorelin, Linaclotide Delayed Release, and Cenicriviroc Data at Digestive Disease Week® 2017
May 01, 2017
Allergan plc (NYSE: AGN) today announced that the company and its collaborators will present clinical and preclinical data for Linzess® (linaclotide) and linaclotide delayed release, Viberzi®...
- Acquisition Adds Best-in-Class Body Contouring Business to Allergan's World-Class Facial Aesthetics, Plastic Surgery & Regenerative Medicine Businesses -
Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimulating Device Proven to Temporarily Increase Tear Production
April 25, 2017
Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical Dystonia and Alzheimer's Disease at the American Academy of Neurology Meeting in Boston
April 20, 2017
Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that it has 13 presentations at the upcoming 69th American Academy of Neurology (AAN) annual meeting taking place April...
Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
April 17, 2017
-- Collaboration Focused on Phase 2b Clinical Trial to Evaluate Use of Allergan's Cenicriviroc (CVC) and Novartis Lead FXR Agonist to Treat NASH -
Allergan Launches Frames of Mind, Encouraging People Living with Migraine to Share Common Experiences Through Art
April 11, 2017
Allergan Receives 2017 ENERGY STAR® Partner of the Year - Sustained Excellence Award from U.S. Environmental Protection Agency
April 10, 2017
Allergan Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk
April 07, 2017
In Recognition of IBS Awareness Month, Allergan and the American Gastroenterological Association Work to Destigmatize the Bowel Health Conversation
Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy
April 06, 2017
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Daphne Karydas will join the Company as Senior Vice President of Global Investor Relations and Strategy,...
Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX® (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD)
April 05, 2017
BOTOX® is currently being studied as a potential treatment option for adult patients with moderate to severe Major Depressive Disorder (MDD)
Allergan plc (NYSE: AGN) today announced that it intends to release first quarter 2017 financial results on Tuesday, May 9, 2017, prior to the open of U.S. Financial Markets.
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
March 27, 2017
Allergan Announces Availability of RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle
March 22, 2017
JUVÉDERM VOLLURE™ XC Approved by U.S. FDA for Correction of Facial Wrinkles and Folds in Adults over the Age of 21
March 20, 2017
First and Only Hyaluronic Acid (HA) Dermal Filler FDA Approved for the Correction of Moderate to Severe Wrinkles and Folds, such as Nasolabial Folds, That Lasts up to 18 Months(1,2*)
- Application Seeks to Expand VRAYLAR Label to Include Phase 3 Clinical Data for the Maintenance Treatment of Schizophrenia-
Allergan Presents Data From 21 Abstracts At The 2017 American Academy Of Dermatology Meeting In Orlando, FL
March 03, 2017
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that it will present 21 Allergan-supported abstracts, a record high for the brand, at the 2017 Annual American...
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the Barclays Global Healthcare Conference in Miami, Florida....
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan Chairman and CEO Brent Saunders will present at the Cowen and Company 37th Annual Health Care Conference...